CYP1A2 and urinary bladder cancer: Haplotype 2 (C/A): The second haplotype, characterized by the C/A genotype of the SNP CYP1A2.163 C.A, showed a prevalence of 93 individuals (54.7%) in the bladder cancer patients and 60 individuals (35.3%) in the control group.